InsiderSignalSign in
← Insider buys

KALV

KalVista Pharmaceuticals, Inc. · Healthcare

Insiders sold $6.8M of KalVista Pharmaceuticals, Inc. in the last 12 months and bought none

$0Bought, 12 mo
$6.8MSold, 12 mo
$1.4BMarket cap
Follow KALV

KALV over the last year

No insider buys filed in this year

KALV after insider buys

3 months after each buy, from the first price a copier could get.

−0.7%Average
−5.3 ptsVs S&P 500
5 of 13Higher

13 buys since 2017 with 3 months of prices.

Every filing

150 insider filings since 2017, newest first

KALVSell

Edward P. Feener · Chief Scientific Officer

$398K−31.0%Feb 21
KALVSell

Christopher Yea · Chief Development Officer

$170K−14.0%Feb 21
KALVSell

Thomas Andrew Crockett · CEO

$351K−11.0%Feb 21
KALVSell

Benjamin L Palleiko · CFO, CBO

$613K−20.0%Feb 16
KALVSell

Thomas Andrew Crockett · CEO

$876K−24.0%Feb 16
KALVSell

Edward P. Feener · Chief Scientific Officer

$423K−28.0%Feb 16
KALVSell

Christopher Yea · Chief Development Officer

$599K−38.0%Feb 16
KALVBuy

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$1.3M+2.0%Feb 8
KALVSell

Thomas Andrew Crockett · CEO

$162K−8.0%Feb 5
KALVBuy

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$1.3M+2.0%Feb 1
KALVBuy

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$1.3M+2.0%Jan 29
KALVBuy

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$1.2M+2.0%Jan 24
KALVBuy

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$1.8M+3.0%Jan 19
KALVBuy

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$334K+1.0%Jan 16
KALVSell

Edward P. Feener · Chief Scientific Officer

$296K−36.0%Jan 12
KALVBuy

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$1.7M+3.0%Jan 10
KALVSell

Edward P. Feener · Chief Scientific Officer

$225K−22.0%Jan 10
KALVBuy

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$721K+1.0%Jan 5
KALVBuy

Venrock Healthcare Capital Partners Iii, L.P. · 10% owner

$6.5M+15.0%Dec 29
KALVSell

Thomas Andrew Crockett · CEO

$360K−19.0%Dec 28
KALVSell

Paul K. Audhya · Chief Medical Officer

$66K−18.0%Nov 21
KALVSell

Benjamin L Palleiko · Pres, CFO, CBO, Sec'y

$107K−10.0%Nov 21
KALVSell

Edward P. Feener · Chief Scientific Officer

$41K−6.0%Nov 21
KALVSell

Christopher Yea · Chief Development Officer

$59K−13.0%Nov 21
KALVSell

Thomas Andrew Crockett · CEO

$122K−9.0%Nov 21
KALVSell

Albert Cha · Director

$189K−100.0%Sep 13
KALVSell

Paul K. Audhya · Chief Medical Officer

$86K−24.0%Aug 21
KALVSell

Benjamin L Palleiko · Pres, CFO, CBO, Sec'y

$140K−12.0%Aug 21
KALVSell

Edward P. Feener · Chief Scientific Officer

$53K−6.0%Aug 21
KALVSell

Christopher Yea · Chief Development Officer

$77K−15.0%Aug 21
KALVSell

Thomas Andrew Crockett · CEO

$160K−9.0%Aug 21
KALVSell

Benjamin L Palleiko · Pres, CFO, CBO, Sec'y

$41K−5.0%May 19
KALVSell

Paul K. Audhya · Chief Medical Officer

$28K−18.0%May 19
KALVSell

Christopher Yea · Chief Development Officer

$26K−7.0%May 19
KALVSell

Thomas Andrew Crockett · CEO

$57K−4.0%May 19
KALVSell

Paul K. Audhya · Chief Medical Officer

$26K−27.0%Feb 23
KALVSell

Benjamin L Palleiko · Pres, CFO, CBO, Sec'y

$38K−6.0%Feb 23
KALVSell

Thomas Andrew Crockett · CEO

$51K−5.0%Feb 23
KALVSell

Thomas Andrew Crockett · CEO

$27K−2.0%Aug 19
KALVSell

Thomas Andrew Crockett · CEO

$171K−8.0%Mar 11
KALVSell

Edward P. Feener · Chief Scientific Officer

$108K−73.0%Nov 3
KALVSell

Christopher Yea · Chief Development Officer

$90K−13.0%Nov 3
KALVSell

Thomas Andrew Crockett · CEO

$172K−7.0%Oct 4
KALVSell

Christopher Yea · Chief Development Officer

$103K−12.0%Aug 4
KALVSell

Edward P. Feener · Chief Scientific Officer

$123K−42.0%Aug 4
KALVSell

Thomas Andrew Crockett · CEO

$241K−7.0%Jul 2
KALVSell

Thomas Andrew Crockett · CEO

$32K−1.0%Jun 22
KALVSell

Thomas Andrew Crockett · CEO

$268K−6.0%Jun 11
KALVSell

Michael David Smith · SVP, Development

$201K−100.0%Jun 3
KALVSell

Edward P. Feener · Chief Scientific Officer

$908K−70.0%Jun 3
Newer filingsOlder filings
About KalVista Pharmaceuticals, Inc.

As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.